We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Appeals Panel Rejects Avastin But CMS, EC Back the Drug
FDA Appeals Panel Rejects Avastin But CMS, EC Back the Drug
July 8, 2011
An FDA appeals hearing panel emphatically recommended nixing the metastatic breast cancer (MBC) indication for Genentech’s Avastin late last month, just as the European Commission (EC) expanded the drug’s use in MBC.